Schizoaffective Disorder (cont.)
Roxanne Dryden-Edwards, MD
Dr. Roxanne Dryden-Edwards is an adult, child, and adolescent psychiatrist. She is a former Chair of the Committee on Developmental Disabilities for the American Psychiatric Association, Assistant Professor of Psychiatry at Johns Hopkins Hospital in Baltimore, Maryland, and Medical Director of the National Center for Children and Families in Bethesda, Maryland.
Melissa Conrad Stöppler, MD
Melissa Conrad Stöppler, MD, is a U.S. board-certified Anatomic Pathologist with subspecialty training in the fields of Experimental and Molecular Pathology. Dr. Stöppler's educational background includes a BA with Highest Distinction from the University of Virginia and an MD from the University of North Carolina. She completed residency training in Anatomic Pathology at Georgetown University followed by subspecialty fellowship training in molecular diagnostics and experimental pathology.
In this Article
- Schizoaffective disorder facts
- What is schizoaffective disorder?
- What are the different types of schizoaffective disorder?
- What are causes and risk factors for schizoaffective disorder?
- What are schizoaffective disorder symptoms and signs?
- How can schizoaffective disorder be diagnosed?
- What are criteria for diagnosis of schizoaffective disorder?
- What is the treatment for schizoaffective disorder?
- What are complications of schizoaffective disorder?
- What is the prognosis of schizoaffective disorder?
- Can schizoaffective disorder be prevented?
- Are there support groups for schizoaffective disorder?
- Where can people find more information on schizoaffective disorder?
- Find a local Psychiatrist in your town
Can schizoaffective disorder be prevented?
Once schizoaffective disorder has occurred, future episodes are best prevented when the person suffering from the illness receives consistent treatment, including medication and psychosocial treatment of their symptoms.
Are there support groups for schizoaffective disorder?
Where can people find more information on schizoaffective disorder?
Abrams DJ, Rojas DC, Arciniegas DB. Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. Neuropsychiatric Disorders Treatment 2008 December; 4(6): 1089-1109.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fifth edition. American Psychiatric Association 2013, Arlington, Virginia.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision. American Psychiatric Association 2000, Washington, D.C.
Baker AL, et al. Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. Journal of Clinical Psychiatry 2010 March; 71(3): 247-254.
Daumit GL, Goldberg RW, Anthony C, et al. Physical activity patterns in adults with severe mental illness. Journal of Nervous and Mental Disease 2005 October; 193(10): 641-646.
Harkavy-Friedman JM, Nelson EA, Venarde DF, Mann JJ. Suicidal behaviour in schizophrenia and schizoaffective disorder: examining the role of depression. Suicide Life-Threat 2004; 34: 66-76.
Laursen TM, Labouriau R, Licht RW, et al. Family history of psychiatric illness as a risk factor for schizoaffective disorder: a Danish register-based cohort study FREE. Archives of General Psychiatry 2005: 62(8): 841-848.
Lysaker PH, Beattie NL, Strasburger AM, et al. Reported history of child sexual abuse in schizophrenia: Associations with heightened symptom levels and poorer participation over four months in vocational rehabilitation. Journal of Nervous and Mental Disease 2005 December; 193(12): 790-795.
Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. The American Journal of Psychiatry 2004 March; 161(3): 473-479.
Schottle D, Schimmelmann BG, Conus P, et al. Differentiating schizoaffective and bipolar I disorder in first-episode psychotic mania. Schizophrenia Research 2012 September; 140(1-3): 31-36.
Smeraldi E, Cavallaro R, Folnegovic-Smalc V, et al. Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Therapeutic Advances in Psychopharmacology 2013 March.
Stauder AD. Group motivational interviewing as a psychotherapeutic intervention for dual diagnosis patients living with a psychotic disorder: critique of the literature. Graduate Journal of Counseling Psychology 2012; 3(1).
Varese F, Smeets F, Drukker M, Lieverse R et al. Childhood Adversities Increase the Risk of Psychosis: A Meta-analysis of Patient-Control, Prospective and Cross-sectional Cohort Studies. Schizophrenia Bulletin 2012.
Vieta E. Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation. Journal of Clinical Psychiatry 2010; 71 (suppl. 2): 14-19.
Viewers share their comments
Get tips on therapy and treatment.